Meningococcemia screening

Jump to navigation Jump to search

Meningococcemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Meningococcemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Meningococcemia screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Meningococcemia screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Meningococcemia screening

CDC on Meningococcemia screening

Meningococcemia screening in the news

Blogs on Meningococcemia screening

Directions to Hospitals Treating Meningococcemia

Risk calculators and risk factors for Meningococcemia screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

Routine screening is not recommended for meningococcemia.

Screening

  • Routine antimicrobial susceptibility testing of meningococcal isolates is not currently recommended.
  • Surveillance of susceptibility patterns in populations should be conducted in order to monitor trends in N. meningitidis susceptibility.
  • State and local health departments should notify the Centers for Disease Control and Prevention (CDC) if resistance to ciprofloxacin or other agents used for treatment or prophylaxis is detected.
  • Passive and active surveillance systems are used to monitor meningococcal disease, which is a reportable disease in the United States. Through a national passive reporting system, state health departments collect and transmit weekly reports of cases to CDC through the National Electronic Telecommunications System for Surveillance (NETSS).
  • The goals of meningococcal surveillance are:
  • To detect outbreaks of meningococcal disease so that appropriate control measures can be promptly instituted, and
  • To assess changes in the epidemiology of meningococcal disease over time to permit the most efficient allocation of resources and formulation of the most effective disease control and prevention policies.
  • Meningococcal serogroup surveillance data are important to monitor the impact of quadrivalent meningococcal conjugate vaccine.
  • Meningococcal serogroup data also help to determine the epidemiologic link between cases in cluster or outbreak situations.[1]

References

  1. "The Centers for Disease Control and Prevention(CDC)".